ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
Morning Overview on MSN
CRISPR boosts a little-known fruit into a big farming win
Goldenberries have long been a niche curiosity, tucked into specialty produce aisles and health food shops while tomatoes and ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...
-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to ...
In a small trial, some people with inherited vision loss experienced improvements in their sight after being treated with CRISPR. When you purchase through links on our site, we may earn an affiliate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback